144 related articles for article (PubMed ID: 28255377)
21. [Use of therapeutic plasmapheresis in the exacerbation period of multiple sclerosis].
Neretin VIa; Kir'iakova VA; Sapfirova VA; Ivanov MI; Volkova EK
Sov Med; 1988; (2):86-9. PubMed ID: 3388103
[No Abstract] [Full Text] [Related]
22. Relapse of multiple sclerosis following acute allergic reactions to plasma during plasmapheresis.
Wirguin I; Shinar E; Abramsky O
J Neurol; 1989 Jan; 236(1):62-3. PubMed ID: 2915232
[TBL] [Abstract][Full Text] [Related]
23. Neurologic indications for therapeutic plasma exchange: an update.
Gwathmey K; Balogun RA; Burns T
J Clin Apher; 2011; 26(5):261-8. PubMed ID: 21915895
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic plasmapheresis in multiple sclerosis (preliminary report)].
Bokonjić R; Kantardzić D; Haracić M
Neurologija; 1984; 32(1-2):3-11. PubMed ID: 6472573
[No Abstract] [Full Text] [Related]
25. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination.
Rodriguez M; Karnes WE; Bartleson JD; Pineda AA
Neurology; 1993 Jun; 43(6):1100-4. PubMed ID: 8170550
[TBL] [Abstract][Full Text] [Related]
26. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.
Lycke J; Zetterberg H
Expert Rev Clin Immunol; 2017 Dec; 13(12):1143-1153. PubMed ID: 29090607
[TBL] [Abstract][Full Text] [Related]
27. [Plasmapheresis in multiple sclerosis].
Fuchs S; Pogglitsch H; Ladurner G; Lechner H
Wien Klin Wochenschr; 1984 Jan; 96(2):67-9. PubMed ID: 6710999
[TBL] [Abstract][Full Text] [Related]
28. Vestibular and ocular motor function prior to and after therapeutic apheresis with small plasmafilter in multiple sclerosis.
Kolev OI; Kenarov P
J Clin Apher; 2016 Oct; 31(5):470-2. PubMed ID: 26332668
[TBL] [Abstract][Full Text] [Related]
29. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis.
Ramunni A; De Robertis F; Brescia P; Saliani MT; Amoruso M; Prontera M; Dimonte E; Trojano M; Coratelli P
Ther Apher Dial; 2008 Jun; 12(3):250-4. PubMed ID: 18503704
[TBL] [Abstract][Full Text] [Related]
30. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
Landi D; De Rossi N; Zagaglia S; Scarpazza C; Prosperini L; Albanese M; Buttari F; Mori F; Marfia GA; Sormani MP; Capra R; Centonze D;
Neurology; 2017 Mar; 88(12):1144-1152. PubMed ID: 28228569
[TBL] [Abstract][Full Text] [Related]
31. [Diagnosis and therapy in multiple sclerosis].
Sailer M
Anasthesiol Intensivmed Notfallmed Schmerzther; 2010 May; 45(5):328-34. PubMed ID: 20455189
[TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis update.
Markowitz CE
Am J Manag Care; 2013 Nov; 19(16 Suppl):s294-300. PubMed ID: 24494618
[TBL] [Abstract][Full Text] [Related]
33. [The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].
Neretin VIa; Gannushkina IV; Zhirnova IG; Sapfirova VA; Kir'iakov VA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(2):17-21. PubMed ID: 3259769
[TBL] [Abstract][Full Text] [Related]
34. Benefit in long-term response and mortality of treatment with intravenous immunoglobulin prior to plasmapheresis in peripheral polyneuropathies.
Parra-Salinas I; González-Rodríguez VP; Gracia Pina JA; Gimeno Lozano JJ; García-Erce JA
Transfus Clin Biol; 2017 Feb; 24(1):9-14. PubMed ID: 27865608
[TBL] [Abstract][Full Text] [Related]
35. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
Kacperska MJ; Jastrzebski K; Tomasik B; Walenczak J; Konarska-Krol M; Glabinski A
J Mol Neurosci; 2015 May; 56(1):154-63. PubMed ID: 25487315
[TBL] [Abstract][Full Text] [Related]
36. [Plasmapheresis and immunosuppressive drugs in the treatment of multiple sclerosis].
Cendrowski W
Neurol Neurochir Pol; 1984; 18(3):259-62. PubMed ID: 6390235
[No Abstract] [Full Text] [Related]
37. [Plasmapheresis in acute phase of multiple sclerosis and neuromyelitis optica].
Matsuo H
Nihon Rinsho; 2014 Nov; 72(11):1999-2002. PubMed ID: 25518384
[TBL] [Abstract][Full Text] [Related]
38. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
Faissner S; Nikolayczik J; Chan A; Hellwig K; Gold R; Yoon MS; Haghikia A
J Neurol; 2016 Jun; 263(6):1092-8. PubMed ID: 27039388
[TBL] [Abstract][Full Text] [Related]
39. Lymphocytoplasmapheresis in multiple sclerosis: preliminary laboratory findings.
Ghezzi A; Zaffaroni M; Caputo D; Guaschino R; Gasco P; Montanini R; Cazzullo CL
Ital J Neurol Sci; 1985 Mar; 6(1):85-7. PubMed ID: 3997466
[TBL] [Abstract][Full Text] [Related]
40. Experience with plasmapheresis in 153 neurologic patients.
Dau PC; Miller RG; Denys EH
Int J Artif Organs; 1982 Jan; 5(1):37-46. PubMed ID: 7068264
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
